LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Search

Lisata Therapeutics

Cerrado

4.52 -0.44

Resumen

Variación precio

24h

Actual

Mínimo

4.48

Máximo

4.54

Métricas clave

By Trading Economics

Empleados

26

Dividendos

By Dow Jones

Próximas Ganancias

26 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

14M

35M

Apertura anterior

4.96

Cierre anterior

4.52

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 feb 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 feb 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 feb 2026, 23:39 UTC

Adquisiciones, fusiones, absorciones

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 feb 2026, 23:38 UTC

Ganancias

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 feb 2026, 23:38 UTC

Ganancias

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 feb 2026, 23:38 UTC

Ganancias

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 feb 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 feb 2026, 23:34 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 feb 2026, 23:34 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 feb 2026, 23:33 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 feb 2026, 23:33 UTC

Ganancias

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 feb 2026, 22:13 UTC

Charlas de Mercado

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 feb 2026, 22:08 UTC

Ganancias

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 feb 2026, 22:07 UTC

Ganancias

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 feb 2026, 22:06 UTC

Ganancias

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 feb 2026, 22:05 UTC

Ganancias

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 feb 2026, 22:05 UTC

Ganancias

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 feb 2026, 22:04 UTC

Ganancias

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 feb 2026, 22:04 UTC

Ganancias

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 feb 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

19 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

19 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

19 feb 2026, 21:43 UTC

Ganancias

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 feb 2026, 21:42 UTC

Adquisiciones, fusiones, absorciones

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 feb 2026, 21:42 UTC

Ganancias

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 feb 2026, 21:41 UTC

Ganancias

Correct: St Barbara 1H Net Loss A$249,000

19 feb 2026, 21:40 UTC

Ganancias

St Barbara 1H Net Loss A$249 Million

19 feb 2026, 21:39 UTC

Ganancias

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 feb 2026, 21:37 UTC

Ganancias

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 feb 2026, 21:37 UTC

Ganancias

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Finanzas

$

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
help-icon Live chat